Eisai: DBV's financing for peanut allergy patch; Eisai divests proton pump inhibitor in China
Plus, news about Palatin, Spero and BioAtla: DBV Technologies' $306M financing: The French biotech could get up to that amount to help advance its peanut allergy patch for children through an ...
Read full article »
Eisai is a Japan-based pharmaceutical company that develops and commercializes prescription medicines and OTC drugs for the healthcare sector.
Read more